Stock STAR STRIDES PHARMA SCIENCE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Strides Pharma Science Limited Bombay S.E.

Equities

STAR

INE939A01011

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 11:00:55 27/06/2024 BST 		5-day change 1st Jan Change
940.7 INR -1.18% Intraday chart for Strides Pharma Science Limited -1.73% +45.08%
05-23 Strides Pharma Science Turns to Consolidated Net Profit in Fiscal Q4; Shares Down 3% MT
05-22 Transcript : Strides Pharma Science Limited, Q4 2024 Earnings Call, May 22, 2024

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 42,303 28,854 75,754 31,121 25,858 86,530 - -
Enterprise Value (EV) 1 64,938 43,620 92,026 31,121 25,858 72,114 86,530 86,530
P/E ratio 13 x 79.3 x 28.2 x -6.76 x -12.7 x -101 x 19.7 x 14.8 x
Yield 0.64% 4.35% 0.3% - 0.52% 0.38% 0.37% 0.37%
Capitalization / Revenue 1.4 x 1.05 x 2.28 x 1.01 x 0.7 x 1.78 x 1.87 x 1.71 x
EV / Revenue 1.4 x 1.05 x 2.28 x 1.01 x 0.7 x 1.78 x 1.87 x 1.71 x
EV / EBITDA 9.3 x 5.4 x 12.1 x -302 x 6.01 x 9.7 x 9.41 x 9.06 x
EV / FCF -15.7 x 52.6 x 41.2 x -7.76 x -51.2 x 15.7 x 12.7 x 10.3 x
FCF Yield -6.36% 1.9% 2.43% -12.9% -1.95% 6.36% 7.9% 9.7%
Price to Book 1.6 x 1.14 x 2.89 x 1.32 x 1.19 x 3.89 x 3.41 x 3.03 x
Nbr of stocks (in thousands) 89,549 89,565 89,681 89,790 90,303 91,917 - -
Reference price 2 472.4 322.2 844.7 346.6 286.4 941.4 941.4 941.4
Announcement Date 10/05/19 20/05/20 27/05/21 24/05/22 25/05/23 22/05/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 30,117 27,520 33,159 30,702 36,884 40,511 46,169 50,750
EBITDA 1 4,548 5,347 6,268 -103.2 4,302 7,433 9,192 9,554
EBIT 1 2,829 3,610 4,205 -2,531 1,869 5,226 6,800 5,746
Operating Margin 9.39% 13.12% 12.68% -8.24% 5.07% 12.9% 14.73% 11.32%
Earnings before Tax (EBT) 1,204 1,619 3,733 -5,417 -2,862 - 5,173 6,905
Net income 1 3,246 363.8 2,684 -4,602 -2,026 -706.1 4,327 4,447
Net margin 10.78% 1.32% 8.1% -14.99% -5.49% -1.74% 9.37% 8.76%
EPS 2 36.24 4.060 29.92 -51.28 -22.49 -7.760 47.70 63.45
Free Cash Flow 1 -2,690 548.1 1,840 -4,012 -505.3 5,502 6,839 8,396
FCF margin -8.93% 1.99% 5.55% -13.07% -1.37% 13.38% 14.81% 16.54%
FCF Conversion (EBITDA) - 10.25% 29.35% - - 74.7% 74.4% 87.89%
FCF Conversion (Net income) - 150.66% 68.53% - - - 158.05% 188.83%
Dividend per Share 2 3.000 14.00 2.500 - 1.500 3.600 3.500 3.500
Announcement Date 10/05/19 20/05/20 27/05/21 24/05/22 25/05/23 22/05/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 8,320 9,085 6,884 7,215 7,944 8,660 9,401 8,971 8,648 9,864 9,300 9,833 10,216 10,799
EBITDA 1 1,661 1,592 -553.5 -10.78 46.05 415 601.5 981.3 1,163 1,556 1,666 1,792 2,096 1,951
EBIT 1,136 1,073 -1,102 -576.4 -562.9 -185.1 -2.47 364.3 561.2 - - - - -
Operating Margin 13.65% 11.81% -16.01% -7.99% -7.09% -2.14% -0.03% 4.06% 6.49% - - - - -
Earnings before Tax (EBT) 728.5 758.9 -2,246 -1,514 -1,069 -588.8 -1,070 67.66 654.4 - - - - -
Net income 378.5 460.9 -2,052 -1,626 -1,217 292.2 -1,359 228.2 -800.3 - - - - -
Net margin 4.55% 5.07% -29.81% -22.53% -15.32% 3.37% -14.46% 2.54% -9.25% - - - - -
EPS - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 04/02/21 27/05/21 06/08/21 10/11/21 10/02/22 24/05/22 29/07/22 14/11/22 24/01/23 25/05/23 02/08/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 22,635 14,766 16,272 - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) 4.977 x 2.761 x 2.596 x - - - - -
Free Cash Flow 1 -2,690 548 1,840 -4,012 -505 5,503 6,839 8,397
ROE (net income / shareholders' equity) 12.7% 1.41% 10.1% -17.9% -8.9% 4.95% 15.8% 16.2%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 296.0 282.0 292.0 263.0 241.0 242.0 276.0 311.0
Cash Flow per Share 49.00 64.30 72.80 - - - - -
Capex 1 3,291 1,500 2,975 1,434 949 2,000 2,000 1,940
Capex / Sales 10.93% 5.45% 8.97% 4.67% 2.57% 4.86% 4.33% 3.82%
Announcement Date 10/05/19 20/05/20 27/05/21 24/05/22 25/05/23 22/05/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Strides Pharma Science Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
941.4 INR
Average target price
993.5 INR
Spread / Average Target
+5.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.39% 43.67B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+26.21% 22.79B
SANDOZ GROUP AG Stock Sandoz Group AG
+21.43% 15.45B
CIPLA LIMITED Stock Cipla Limited
+18.82% 14.29B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+53.37% 12.83B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.88% 6.52B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+12.62% 5.59B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. STAR Stock
  4. STAR Stock
  5. Financials Strides Pharma Science Limited